Unite to End TB: Collaborating to Identify Local Strategies for Tuberculosis Prevention & Care

Mar 24, 2017 | Kim Rodgers

By: Aurimar Ayala, MPH, Maricopa County Department of Public Health

World Tuberculosis (TB) Day, on March 24, is an annual event to commemorate Dr. Robert Koch’s 1882 discovery of Mycobacterium tuberculosis. This year’s theme, “Unite to End TB,” is a nod to the many organizations in the United States (U.S.) and worldwide working in close partnership to eliminate TB. In Arizona, approximately 50% of TB cases are from Maricopa County, the state’s most populous county and the fourth most populous in the U.S. In 2012, Maricopa County Department of Public Health (MCDPH) joined nine other sites across the nation to participate in the Tuberculosis Epidemiologic Studies Consortium (TBESC) II, a Centers for Disease Control and Prevention (CDC) effort to evaluate diagnostic tests for latent tuberculosis infection (LTBI). TBESC II aims to coordinate and strengthen TB research among a diverse group of researchers and organizations including TB control programs and academic institutions. The Consortium represents a unique opportunity for our local health department to collaborate on collecting multi-site data on LTBI in the U.S. and contribute to the collection of generalizable data for the country. At the same time, by participating in this effort, we can also work on identifying local strategies for LTBI and TB prevention and care that can be directly applied at our public health clinic and targeted to the patients that we see.

Establishing Current Research Priorities
Persons with LTBI are at increased risk for developing active TB disease. Therefore, a critical component of TB prevention and control is the identification and treatment of LTBI in populations at high risk of exposure to TB in order to prevent progression to active TB disease among these groups.

LTBI tests include the tuberculin skin test (TST); the Interferon-gamma release assays (IGRAs); T-SPOT.TB (T-SPOT); and QuantiFERON-TB Gold In-Tube (QFT). There is no gold standard for tuberculosis testing and TST interpretations are complicated by false positive results associated with Bacillus Calmette–Guérin (BCG) vaccination. TBESC II’s main goals are to determine the agreement between these tests and the ability of these tests to predict progression from LTBI to TB disease.

The primary TBESC II study is a prospective cohort of persons at high risk of exposure to Mycobacterium tuberculosis or progression to TB disease. About 6,000 patients are enrolled every year from all sites with a total enrollment goal of 42,000 during a seven-year period. At our local public health clinic site, we contribute about 600 participants to the overall study per year. Over 90% of participants from our site are foreign-born from countries at high or medium risk for TB transmission.

Enrollment criteria and study procedures are standardized across sites. At enrollment, participants are tested for LTBI with the three diagnostic tests: TST, QFT and T-SPOT. The goal is to examine agreement between tests for the entire cohort but also by key groups of interest – including persons with HIV infection, children, refugees, and people that are immunocompromised – in an effort to determine which subgroups are more likely to benefit from various testing strategies. Additionally, researchers are examining changes in cut-off values to determine if sensitivity and specificity can be increased, while also assessing cost and cost-effectiveness of tests. The study will also describe the characteristics of participants that progress to active TB disease.

Collaborating to Strengthen Tuberculosis Research
To determine research priorities and encourage and strengthen collaboration from the different sites, the Consortium has created committees to review research proposals and workgroups that focus on shared topics of interest. These workgroups provide spaces where researchers from different sites can work together. The Consortium encourages each site to analyze their own site data or proposed concept papers to explore research topics using the cohort as a whole. For example, at MCDPH we recently analyzed our site’s data to determine LTBI prevalence and LTBI treatment acceptance and completion rates. We will be using the results of this analysis to increase LTBI treatment compliance in our clinic by focusing on strategies to decrease the number of patients that are lost to follow-up. We also plan to address reasons for refusal of treatment after the person has initially accepted treatment. We are very interested in taking an in-depth look at ways to increase treatment acceptance and compliance rates. As such, we are also part of a group of multi-site researchers at TBESC II exploring this topic for the entire cohort. Working with other sites has great benefits for us at the local level. We can share our experience but also learn from the point of view of other researchers. We are able to bounce ideas around and challenge each other to ensure the highest research standards in our publications.

Looking Forward: Other Research Objectives and Future Plans
TBESC II plans to work on strategies to pinpoint populations that are at high risk for TB development but not receiving LTBI services; identify providers for these populations; and gather data about their TB services in an effort to design strategies to maximize diagnosis and treatment in these groups. The Consortium is working on the development and implementation of a data management system that can be used to manage LTBI patients receiving clinical services and can also be used as a surveillance tool. Our site has been pilot testing this system and providing feedback from the perspective of our clinic with the goal of creating a system that can be used by a variety of partners nationwide.

Learn more about TBESC II and MCDPH, and feel free to contact TBESC at TBESC@cdc.gov with questions. For more information about how the CDC is working to support public health efforts to eliminate tuberculosis, check out this “Dear Colleague” letter and these resources.


637020799465370000

About Kim Rodgers

Kim Rodgers is the Communications Manager at NACCHO.

More posts by Kim Rodgers

0 Comments

Related Posts

Cdc badge small
  • Tools & Resources

CDC Report: Temporary Reassignment of Personnel Requests...

CDC recently updated its flexibilities guidance for recipients and applicants...

Jul 09, 2020 | Kim Rodgers

CDC Report: Temporary Reassignment of Personnel Requests...

Jennifer kertanis headshot 24152456360
  • Opportunity

Top Moments From Day Two at NACCHO 360

Welcome to the final day of NACCHO 360! Yesterday NACCHO Chief Executive...

Jul 09, 2020 | Taylarr Lopez

Top Moments From Day Two at NACCHO 360

COVID VC Screenshot
  • COVID-19
  • Tools & Resources
  • Emergency Response
  • Infectious Disease

NACCHO’s COVID-19 Virtual Community Now Available to All...

NACCHO has opened our COVID-19 Virtual Community to all local health department...

Jul 08, 2020 | Kim Rodgers

NACCHO’s COVID-19 Virtual Community Now Available to All...

Sync2020 logos horizontal 1024x304
  • HIV, STI, & Viral Hepatitis

Scholarships Available: SYNChronicity 2020 Conference –...

SYNC 2020, the National Conference for HIV, HCV, STI and LGBTQ Health, is...

Jul 08, 2020 | Julia Zigman

Scholarships Available: SYNChronicity 2020 Conference –...

  • COVID-19
  • HIV, STI, & Viral Hepatitis
  • Research & Reports

Kaiser Family Foundation: Reduction in Sexual and...

The Kaiser Family Foundation released a new issue brief, Potential Impacts of...

Jul 08, 2020 | Julia Zigman

Kaiser Family Foundation: Reduction in Sexual and...

2000px US CDC logo
  • HIV, STI, & Viral Hepatitis

New Recommendations for Hepatitis Vaccination

CDC has released new recommendations for hepatitis A virus (HAV) vaccination,...

Jul 08, 2020 | Julia Zigman

New Recommendations for Hepatitis Vaccination

TAG Logo
  • HIV, STI, & Viral Hepatitis
  • Research & Reports

Treatment Action Group 2020 Pipeline Report Now Available

Treatment Action Group (TAG) recently published their 2020 Pipeline Report, an...

Jul 08, 2020 | Julia Zigman

Treatment Action Group 2020 Pipeline Report Now Available

Pr EP injectable
  • HIV, STI, & Viral Hepatitis
  • Research & Reports

New Study: Injectable PrEP is Safe and Highly Effective

New data further shows an injectable antiretroviral for HIV pre-exposure...

Jul 08, 2020 | Julia Zigman

New Study: Injectable PrEP is Safe and Highly Effective

MMWR
  • HIV, STI, & Viral Hepatitis
  • Research & Reports

HIV Testing Trends at Visits to Physician Offices,...

A recent report from CDC shows low rates of HIV testing in physician offices,...

Jul 08, 2020 | Julia Zigman

HIV Testing Trends at Visits to Physician Offices,...

Back to Top